Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).

BACKGROUND In the CAPTURE (c7E3 Fab Anti Platelet Therapy in Unstable REfractory angina) trial, 1265 patients with refractory unstable angina were treated with abciximab or placebo, in addition to standard treatment from 16 to 24 hours preceding coronary intervention through 1 hour after intervention. To investigate the incidence of recurrent ischemia and the ischemic burden, a subset of 332 patients (26%) underwent continuous vector-derived 12-lead ECG-ischemia monitoring. METHODS AND RESULTS Patients were monitored from start of treatment through 6 hours after coronary intervention. Ischemic episodes were detected in 31 (18%) of the 169 abciximab and in 37 (23%) of the 163 placebo patients (NS). Only 9 (5%) of abciximab versus 22 (14%) of placebo patients had >/=2 ST episodes (P<0.01). In patients with ischemia, abciximab significantly reduced total ischemic burden (P<0.02), which was calculated alternatively as the total duration of ST episodes per patient, the area under the curve of the ST vector magnitude during episodes, or the sum of the areas under the curves of 12 leads during episodes. Twenty-one patients (6%) suffered a myocardial infarction (MI) (18) or died (3) within 5 days of treatment. The presence of asymptomatic and symptomatic ST episodes during the monitoring period preceding coronary intervention was associated with an increased relative risk of these events of 3.2 (95% CI 1.4, 7.4) and 4.1 (95% CI 1.4, 12.2), respectively. CONCLUSIONS Recurrent ischemia predicts MI or death within 5 days of follow-up. Treatment with abciximab is associated with a reduction of frequent ischemia and a reduction of total ischemic burden in patients with refractory unstable angina. As such, patients with ischemia derive particularly high benefit from abciximab.

[1]  Ric,et al.  CARDIAC TROPONIN T LEVELS FOR RISK STRATIFICATION IN ACUTE MYOCARDIAL ISCHEMIA , 2000 .

[2]  C. Heeschen,et al.  Value of troponins in predicting therapeutic efficacy of abciximab in patients with unstable angina , 1998 .

[3]  M L Simoons,et al.  Comparison of usefulness of computer assisted continuous 48-h 3-lead with 12-lead ECG ischaemia monitoring for detection and quantitation of ischaemia in patients with unstable angina. , 1997, European heart journal.

[4]  Stgrp Capture,et al.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.

[5]  T. Böhm,et al.  Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial. , 1997, European heart journal.

[6]  F. Harrell,et al.  Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia , 1996 .

[7]  J. Huisman.  The Netherlands , 1996, The Lancet.

[8]  P. Armstrong,et al.  Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial. , 1996, European heart journal.

[9]  L. Wallentin,et al.  Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group. , 1996, Circulation.

[10]  P. Bossuyt,et al.  Incidence and follow-up of Braunwald subgroups in unstable angina pectoris. , 1995, Journal of the American College of Cardiology.

[11]  A. Folsom.  Epidemiology of fibrinogen. , 1995, European heart journal.

[12]  K. Swedberg,et al.  Vectorcardiographic monitoring to assess early vessel patency after reperfusion therapy for acute myocardial infarction. , 1995, European heart journal.

[13]  R. Califf,et al.  Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months , 1994, The Lancet.

[14]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[15]  H. Weisman,et al.  Randomized Trial of a GPIIb/IIIa Platelet Receptor Blocker in Refractory Unstable Angina , 1994, Circulation.

[16]  R. Califf,et al.  Continuous 12‐Lead ST‐Segment Recovery Analysis in the TAMI 7 Study Performance of a Noninvasive Method for Real‐Time Detection of Failed Myocardial Reperfusion Detection of Failed Myocardial Reperfusion , 1993, Circulation.

[17]  G. Rosano,et al.  Unstable angina: role of silent ischemia and total ischemic time (silent plus painful ischemia), a 6-year follow-up. , 1992, Journal of the American College of Cardiology.

[18]  E. Braunwald,et al.  Unstable angina. A classification. , 1989, Circulation.

[19]  P. Armstrong,et al.  ST segment shift in unstable angina: pathophysiology and association with coronary anatomy and hospital outcome. , 1989, Journal of the American College of Cardiology.

[20]  K. Nademanee,et al.  Prognostic significance of silent myocardial ischemia in patients with unstable angina. , 1987, Journal of the American College of Cardiology.

[21]  M. Weisfeldt,et al.  Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. , 1986, The New England journal of medicine.

[22]  M J Davies,et al.  Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. , 1985, British heart journal.

[23]  E. Falk.  Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. , 1985, Circulation.

[24]  G. Dower,et al.  On Deriving the Electrocardiogram from Vectorcardiographic Leads , 1980, Clinical cardiology.